Details

Autor(en) / Beteiligte

• Nan, Yue-Min
• Zheng, Huan-Wei
• Sun, Dian-Xing
• An, Chun-Mian
• Li, You-Sheng
• Kong, Li
• Dai, Er-Hei
• Zhang, Yu-Guo
• Zhao, Su-Xian
• Su, Shan-Shan
• Jia, Yan-Hong

Titel

Study of using an individualized treatment strategy to treat patients with chronic hepatitis C

Ist Teil von

• Zhonghua gan zang bing za zhi, 2013-01, Vol.21 (1), p.23

Ort / Verlag

China

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• To investigate the outcomes of chronic hepatitis C (CHC) patients treated with antiviral regimens of interferon (IFN) plus ribavirin (RBV) using individualized doses and durations. This study was designed as an open-label, prospective clinical trial to analyze the virological responses of 169 CHC patients who received individualized dosages of IFNa-2b or pegylated (Peg)IFNa-2a combined with RBV based on their weight ( less than 60 kg or more than or equal to 60 kg), age (less than 65 years or 65-75 years), morbid state (liver cirrhosis or not), and complications (such as heart disease, diabetes, thyroid disorder). Treatment duration was calculated using the time required to induce HCV RNA negativity. The rates of virological response and adverse effects among the different groups were compared. The IFNa-2b treatment was given to 116 patients, and PegIFNa-2a was given to 53 patients. Compared to the IFNa-2b group, the PegIFNa-2a group showed significantly higher rates of complete early virological response (cE